All Updates

All Updates

icon
Filter
Funding
Ability Biologics raises USD 18 million in seed funding to develop novel immunomodulators
AI Drug Discovery
Jun 18, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
AI Drug Discovery

AI Drug Discovery

Jun 18, 2024

Ability Biologics raises USD 18 million in seed funding to develop novel immunomodulators

Funding

  • AI-powered antibody therapeutics discovery company Ability Biologics has raised USD 18 million in a seed funding round led by Amplitude Ventures, with participation from Fonds de solidarité FTQ, Investissement Québec, Charles River Laboratories, Theodorus, and Alexandria Venture Investments.

  • The funds will be used to develop Ability's AI-enabled AbiLeap discovery platform, which generates logic-gated, fully human antibodies targeting specific tissues based on certain conditions, such as pH and temperature variations, for enhanced therapeutic selectivity and potency.

  • Canada-based Ability Biologics is focused on developing highly specific and selective antibody therapeutics to address unmet medical needs in cancer and autoimmune diseases. The company leverages its proprietary AbiLeap discovery platform, which uses AI and a database of antigen-antibody interactions.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.